The combination of DNA-PK and PARP inhibitors, as demonstrated in xenograft and patient-derived xenograft models, increased genomic instability, growth inhibition, and apoptosis in breast cancer, and reduced the growth of hepatocellular carcinoma.64,65 Nedisertib is currently being investigated in multiple clinical trials as a radiosensitizer across various tumor types.66 One study currently recruiting is conducted with patients suffering from castrate-resistant PCa undergoing treatment with radium-223 (NCT04071236). This evidence concerns the gene PARP1 and breast carcinoma.